Sensei Biotherapeutics (SNSE) has released an update to notify the public and investors about its officers.
Samuel Broder, MD has stepped down from his role on the Board of Directors at Sensei Biotherapeutics, Inc., where he served for almost five years. His departure is not due to any disputes over the company’s operations or policies. Despite his resignation, Dr. Broder will continue to provide his expertise as a consultant, offering strategic advice on the scientific and clinical development aspects of the company’s product candidates.
For further insights into SNSE corporate activity, check out TipRanks’ Insiders Trading Activity page.
For a comprehensive understanding of the announcement, you can read the full document here.
